Valuation: Immunic, Inc.

Market Cap 101M 90.29M 83.41M 75.59M 141M 9.6B 144M 1B 397M 5.03B 379M 371M 15.85B P/E 2026 *
-2.06x
P/E 2027 * -3.12x
Enterprise Value -179M -160M -147M -134M -250M -16.97B -254M -1.77B -703M -8.89B -671M -657M -28.04B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.03%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Immunic, Inc.

1 day+2.63%
1 week+6.31%
Current month-20.32%
1 month-20.92%
3 months-48.11%
6 months-19.31%
Current year+38.84%
1 week 6.81
Extreme 6.81
7.85
1 month 6.35
Extreme 6.35
9.94
Current year 5.37
Extreme 5.372
17.43
1 year 5.06
Extreme 5.062
17.43
3 years 5.06
Extreme 5.062
21.1
5 years 5.06
Extreme 5.062
145
10 years 5.06
Extreme 5.062
289.9
Manager TitleAgeSince
Chief Executive Officer 48 31/05/2026
Director of Finance/CFO 58 16/04/2020
President 49 11/07/2024
Director TitleAgeSince
Director/Board Member 59 31/03/2019
Director/Board Member 64 18/11/2019
Director/Board Member 75 25/04/2023
Date Insider Type Main position Quantity % Market Cap. Importance
16/09/26
BVF Partners LP
OtherCompany 25,370 0.1859%
16/09/26 Free

Director

25,370 0.1859%
06/08/26 Free

Director

50,740 0.3725%
Change 5-day change 1-year change 3-year change Capi.($)
+2.63%+6.31%-4.99%-35.00% 101M
+2.41%+0.29%+42.02%+71.57% 64.69B
-0.15%+7.50%+11.01%+73.48% 54.78B
+0.57%+4.60%+10.07%+92.86% 53.49B
+0.37%+4.67%+27.03%+52.07% 45.98B
-1.21%+2.32%+21.80%+123.81% 42.94B
-0.37%+5.07%+249.91%+918.74% 40.08B
+0.05%+0.21%+18.26%+58.53% 33.52B
-0.38%+5.68%+36.43%+27.54% 23.67B
+1.19%-4.98%+29.01%-0.65% 23.97B
Average +0.51%+2.80%+44.06%+138.29% 38.32B
Weighted average by Cap. +0.39%+2.73%+47.56%+158.52%

Financials

2026 *2027 *
Net sales - -
Net income -138M -123M -114M -103M -193M -13.1B -196M -1.37B -543M -6.87B -518M -507M -21.65B -149M -133M -123M -112M -209M -14.19B -212M -1.48B -587M -7.43B -561M -549M -23.43B
Net Debt -280M -250M -231M -209M -391M -26.57B -398M -2.78B -1.1B -13.92B -1.05B -1.03B -43.89B -404M -361M -333M -302M -565M -38.33B -574M -4.01B -1.59B -20.08B -1.52B -1.48B -63.32B
Projected Income Statement - Annual - Immunic, Inc.
Logo Immunic, Inc.
Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.
Employees
100
Date Price Change Volume
23/10/26 US$7.410 +2.63% 367,164
22/10/26 US$7.220 -3.48% 473,362
21/10/26 US$7.480 +0.94% 329,878
20/10/26 US$7.410 +6.01% 429,665
19/10/26 US$6.990 +0.29% 319,803
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Immunic, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
7.410USD
Average target price
43.09USD
Spread / Average Target
+481.52%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Immunic, Inc.
  1. Stock Market
  2. Stocks
  3. IMUX Stock